Background and Market Entry of Generic Approval

The U.S. Food and Drug Administration (FDA) issued a Final Approval for Alembic Pharmaceuticals Limited's 0.5mg Fingolimod capsules for the treatment of multiple sclerosis on April 24, 2026. This approval is expected to further accelerate the entry of generic drugs into the market, following the invalidation of Novartis's original blockbuster drug, Gilenya. Alembic has secured a strong portfolio that will enable it to increase drug accessibility in the U.S. market and provide affordable treatment options for patients with multiple sclerosis. Obtaining final regulatory approval is a crucial turning point that will allow it to gain an advantage in price competition with multinational pharmaceutical companies.

Drug Mechanism and Scope of Indications

Fingolimod is classified as a sphingosine 1-phosphate receptor modulator and works by blocking the efflux of lymphocytes from lymph nodes, thereby reducing inflammatory damage in the central nervous system. With this ANDA (Abbreviated New Drug Application) approval, it can now be prescribed for the treatment of relapsing forms of multiple sclerosis in pediatric and adult patients aged 10 years and older. In particular, it covers a broad range of indications, from clinically isolated syndrome to relapsing-remitting and active secondary progressive disease. This is a key factor that will significantly strengthen Alembic's position in the oral disease-modifying therapy (DMT) market, which offers improved convenience of administration.

U.S. Market Size and Competitive Landscape

As of December 2025, the annual market size for 0.5mg Fingolimod in the U.S. is estimated at approximately $145 million, reflecting the price decline following the entry of generics. Gilenya's global peak sales were close to $3 billion in the past, but in 2024, sales fell by more than 40% year-on-year to around $600 million, reflecting the impact of the patent cliff. The market currently includes competing drugs such as Sanofi's Aubagio and Biogen's Tecfidera, and numerous generic developers are competing to gain market share. In this situation, Alembic plans to prioritize securing public insurance coverage and formulary listing in order to expand its market share based on its manufacturing cost competitiveness.

Future Financial Prospects and Risk Management

For generic drugs, whether or not the pharmacy benefit manager (PBM) includes the drug in its formulary is a key factor that will determine the success of initial sales growth. Alembic aims to maintain stable operating profit margins by operating a large-scale active pharmaceutical ingredient (API) production facility in India, even under rapid price pressure. However, additional remaining patent litigation with the original developer, Novartis, and price competition from competitors may pose short-term margin reduction risks. Nevertheless, if it can demonstrate a stable supply chain in the U.S. market, it will solidify its position as a reliable generic partner in the global multiple sclerosis treatment market in the medium to long term.